Masood Azeem Siddiqui, J Pharma Care Health Sys 2015, 2:5
http://dx.doi.org/10.4172/2376-0419.C1.009

OMICS International
conferenceseries.com

Pharmaceutical Summit and Expo

October 08-10, 2015 New Delhi, India

Treatment of COPD with Umeclidinium bromide-Vilanterol combination

Masood Azeem Siddiqui
Deccan School of Pharmacy, India

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by airflow limitation that is not fully reversible and is usually progressive during follow-up. It is estimated that the prevalence of the disease that is clinically significant is 10.1% in adults aged 40 years and older, and males, current or former smokers, and the elderly are more commonly affected. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Combining bronchodilators is an effective approach, as they demonstrate synergic action at a cellular level and have additive clinical benefits and fewer adverse events compared with increased doses of the monocomponents. Novel fixed-dose combinations of long-acting β2-agonists/long-acting muscarinic antagonists in one inhaler have been approved for clinical use by the US Food and Drug Administration and the European Medicines Agency. The US Food and Drug Administration (FDA) approved umeclidinium and vilanterol powder for inhalation (Anoro Ellipta, GlaxoSmithKline). The drug is the first combo bronchodilator treatment indicated for once-daily, long-term maintenance treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD). Novel fixed-dose combinations of long-acting β2-agonists/long-acting muscarinic antagonists in one inhaler have been approved for clinical use by the US Food and Drug Administration and the European Medicines Agency. This review focuses on published clinical trials about the fixed-dose combination of umeclidinium/vilanterol trifenatate in patients with COPD. Results from six studies (five of them of 12 weeks' duration and one that lasted 1 year, including more than 6,000 patients in total) showed that umeclidinium/vilanterol trifenatate improved lung function, dyspnea, and health-related quality of life and decreased the exacerbation rate with no serious adverse events.

Biography

Masood Azeem Siddiqui is a Undergraduate student of Deccan School of Pharmacy pursuing Doctor of Pharmacy (PharmD D V/VI) affiliated to Jawaharlal Nehru Technological University.

azeemroxz@gmail.com

Notes: